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Chronic bronchitis, also known as chronic mu-
cus hypersecretion, is common in cigarette 
smokers and is a key component of chronic ob-
structive pulmonary disease (COPD). After the 
publication of the seminal study by Fletcher and 
Peto in the 1970s,1 chronic bronchitis was recog-
nized as being associated with cigarette smok-
ing and conferring a predisposition to lower 
respiratory infections, but was reported as not 
influencing the progressive airway obstruction 
that is characteristic of COPD.2 However, a num-
ber of later studies showed that chronic bronchi-
tis was indeed not a benign feature of COPD and 
was clearly linked to disease progression, hospi-
tal admission, and mortality.3
Recent data suggest that chronic bronchitis 
may particularly develop in smokers during 
middle age and runs a dynamic course, and the 
longer a patient with COPD has chronic bron-
chitis, the faster airway disease progresses.4 Pa-
tients with chronic bronchitis are more prone to 
exacerbations of their COPD than those without 
chronic bronchitis, and thus sputum production 
is more common in the frequent-exacerbation 
phenotype.5 This is not surprising, because chron-
ic bronchitis is associated with airway bacterial 
infection and increased airway inflammation.
Chronic bronchitis is classically diagnosed 
from the patient’s history and defined as 3 con-
secutive months of cough and sputum produc-
tion over a period of 2 years.6 However, symp-
toms of chronic bronchitis may be variable over 
time, decreasing with smoking reduction or 
cessation and increasing with COPD exacerba-
tions.4 Because chronic bronchitis is an impor-
tant risk factor for the development and progres-
sion of COPD, early diagnosis in these patients 
is important. It would advance the art if there 
were a validated biomarker for chronic bronchi-
tis, because diagnosis based on patient report 
may not be accurate.
In this issue of the Journal, Kesimer and col-
leagues describe the relationship between airway 
mucins and features of chronic bronchitis.7 Mu-
cus that is formed in the airways is a protective 
barrier and consists of globular proteins, macro-
molecular mucins (especially MUC5AC and 
MUC5B), and water. Airway mucins are thought 
to be important in airway mucus transport, but 
when mucin levels rise above a threshold, the 
“two-gel hypothesis,” detailed in the report by 
Kesimer et al., predicts that mucus accumulation 
occurs, leading to sputum production, increased 
airway inflammation, infection, and airflow ob-
struction, which are features consistent with 
progressive COPD.8
In a large, well-phenotyped cohort of the Sub-
populations and Intermediate Outcome Measures 
in COPD Study (SPIROMICS), Kesimer and col-
leagues test the hypothesis that airway mucin 
concentrations are associated with sputum pro-
duction in COPD and are also a marker of dis-
ease severity. The results show that airway mucin 
levels are higher in current or former smokers 
with sputum production than in persons with-
out sputum production or those who have never 
smoked. Airway mucins are also related to the 
severity of COPD and increase with worsening 
disease. Patients with COPD who had two or 
more exacerbations in the previous year had 
higher airway mucin levels than those with no 
exacerbations. This was expected, because exac-
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erbation frequency is associated with chronic 
bronchitis.5 However, only 36 patients in this 
study had two or more exacerbations in the pre-
vious year, and thus larger studies are needed to 
test the relationship between exacerbation fre-
quency and airway mucin levels. SPIROMICS 
participants with chronic bronchitis who were 
symptomatic had higher airway mucin levels 
than those who were asymptomatic, even when 
spirometric values were normal; this is an inter-
esting finding, because symptoms are important 
drivers of disease progression and exacerbation.9 
Computed tomographic (CT) scans were per-
formed in the SPIROMICS cohort, and airway 
mucin levels were higher in participants who 
had a diagnosis of chronic bronchitis with or 
without emphysema on CT than in those with-
out chronic bronchitis.
Other respiratory conditions, such as asthma, 
are also associated with increased mucus hyper-
secretion, and approximately 15% of the current 
or former smokers in the SPIROMICS cohort 
reported current asthma. These participants had 
higher airway mucin levels than controls who 
had never smoked, and the influence of asthma 
on mucin levels was maintained after adjustment 
for smoking. A diagnosis of childhood asthma 
also was associated with higher mucin levels, 
but there was no relationship between airway 
mucin levels and asthma biomarkers. The data 
confirmed the predominance of MUC5B in 
COPD10 as concentrations increased with greater 
severity of disease, but also showed that MUC5AC 
concentrations rise disproportionately with smok-
ing, especially in mild-to-moderate disease.
Finally, the authors tested whether airway 
mucins could be used as a biomarker of chronic 
bronchitis, but the receiver-operating-character-
istic analysis was suboptimal in the SPIROMICS 
cohort. However, results in a small independent 
cohort were more favorable. The variability that 
was observed may be due to the definitions of 
chronic bronchitis currently being used or, more 
likely, the use of highly codified methods for 
gathering sputum specimens in the independent 
cohort. Chronic bronchitis is also variable over 
time, and efforts must now be made to improve 
and validate a new definition of the disorder.
This important study shows that airway mu-
cins are related to smoking, respiratory symp-
toms, and disease severity and exacerbations in 
COPD and further consolidates the central role 
of chronic bronchitis in COPD. Airway mucins 
are a key target for the development of new inter-
ventions in COPD. Further study is needed to 
understand the mechanisms of how mucins con-
tribute to the development of airway inflamma-
tion and the progression of airflow obstruction. 
Airway mucins also show promise as a biomark-
er of chronic bronchitis, but first more work is 
needed to refine the definition and detection of 
the disorder. However, we now know that chron-
ic bronchitis occurs in middle age in smokers, 
before airflow obstruction is even detected. Thus, 
the exciting prospect is that airway mucins may 
eventually predict who will have disabling symp-
toms from COPD.
Disclosure forms provided by the author are available with the 
full text of this editorial at NEJM.org.
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